Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status

Recent collaboration agreements between the company and researchers at the Moffitt Cancer Center and the Buck Institute for Research on Aging will further its "intention of building a portfolio of oncology-related assays using selected-reaction monitoring," said an official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.